Janux Therapeutics/$JANX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Ticker
$JANX
Sector
Primary listing
Employees
108
Headquarters
Website
JANX Metrics
BasicAdvanced
$911m
-
-$1.84
2.57
-
Price and volume
Market cap
$911m
Beta
2.57
52-week high
$35.34
52-week low
$12.12
Average daily volume
1.3m
Financial strength
Current ratio
17.008
Quick ratio
16.954
Long term debt to equity
2.028
Total debt to equity
2.291
Profitability
EBITDA (TTM)
-155.004
Gross margin (TTM)
-829.54%
Net profit margin (TTM)
-833.60%
Operating margin (TTM)
-1,143.11%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-9.44%
Return on equity (TTM)
-11.72%
Valuation
Price to revenue (TTM)
67.651
Price to book
0.97
Price to tangible book (TTM)
0.97
Price to free cash flow (TTM)
-11.836
Free cash flow yield (TTM)
-8.45%
Free cash flow per share (TTM)
-1.262
Growth
Revenue change (TTM)
47.10%
Earnings per share change (TTM)
34.83%
3-year revenue growth (CAGR)
14.83%
3-year earnings per share growth (CAGR)
4.49%
What the Analysts think about JANX
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
JANX Financial Performance
Revenues and expenses
JANX Earnings Performance
Company profitability
JANX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs